FindTrial
Sign In

Sutent

DRUG9 trials

Sponsors

Pfizer, University of Michigan Rogel Cancer Center, US Oncology Research, Baylor Breast Care Center, Assistance Publique - Hôpitaux de Paris

Conditions

Advanced DiseaseAdvanced or Metastatic Renal Cell CarcinomaBladder CancerCarcinoma, Renal CellFibrolamellar Hepatocellular CarcinomaGastrointestinal NeoplasmHepatocellular CarcinomaMetastatic Breast Cancer

Phase 1

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
TerminatedNCT00905021
Baylor Breast Care CenterMetastatic Breast Cancer
Start: 2010-03-31End: 2012-02-29Updated: 2020-07-24

Phase 2

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
TerminatedNCT00393796
University of Michigan Rogel Cancer CenterBladder Cancer
Start: 2006-05-31End: 2012-12-31Updated: 2014-11-13
Sunitinib Non Small Cell Lung Cancer Patients Over 70
CompletedNCT00864721
US Oncology ResearchNon Small Cell Lung Cancer
Start: 2009-02-28End: 2012-07-31Updated: 2018-10-16
Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
TerminatedNCT01215565
Assistance Publique - Hôpitaux de ParisFibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma
Start: 2009-10-31End: 2012-05-31Updated: 2014-03-13
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
TerminatedNCT01215578
Assistance Publique - Hôpitaux de ParisAdvanced Disease, Neuroendocrine Tumors, Pancreatic Neoplasms +1
Start: 2008-10-31End: 2014-12-31Updated: 2015-04-30

Unknown Phase

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
NCT00094029
PfizerGastrointestinal Neoplasm
Start: 2004-09-30End: 2011-10-31Updated: 2012-03-09
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
NCT00130897
PfizerCarcinoma, Renal Cell
Start: 2005-07-31End: 2011-11-30Updated: 2012-03-09
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
CompletedNCT00684645
PfizerMetastatic Renal Cell Carcinoma
Start: 2008-06-30End: 2011-04-30Updated: 2012-08-21
Study In Patients With Kidney Cancer Treated With Sutent
CompletedNCT00873210
PfizerAdvanced or Metastatic Renal Cell Carcinoma, Renal Cancer
Start: 2009-05-31End: 2011-11-30Updated: 2012-11-09

Related Papers

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol
BMJ Open2020-07-0120 citations
Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.
2016-09-238 citations
Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN).
Journal of Clinical Oncology2016-02-012 citations
Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
2016-01-1549 citations
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
2015-01-1374 citations
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
2009-07-15430 citations